A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants
Condition: Healthy Volunteers; Asthma
Intervention: melrilimab (GSK3772847) 70 milligram (mg); melrilimab (GSK3772847) 140 milligram (mg); Placebo
Intervention description: melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial.; Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL); Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial.
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Single Group Assignment
Intervention model description: This is a single arm study.
Masking: Double (Participant, Investigator)
Masking description: This is a double blind study and participants and investigator will be masked.
Enrollment: 65.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Pharmacokinetics; Pharmacodynamics; Safety; GSK3772847; Tolerability

Summary:

      GSK3772847, an anti-interleukin (IL) 33-receptor monoclonal antibody, is a novel treatment
      for asthma. The purpose of this study to evaluate the safety and tolerability, PK and PD of
      single ascending doses of GSK3772847 administered subcutaneously (SC) to healthy
      participants. This study will also establish the bioavailability of SC formulation and
      evaluate the safety in particular injection site tolerability of route. Participants will
      either receive a single dose of 70 milligram (mg) GSK3772847 or placebo in (Cohort 1) and 140
      mg GSK3772847 or placebo in Cohorts 2, 3 (Japanese participants) and 4 (Chinese
      participants). The site of injection will be upper arm; abdomen or thigh for cohorts 1 and 2
      with cohorts 3 and 4 will receive injections in the upper arm only. Approximately, the total
      duration of study will be up to 89 days.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Participants age in between 18 to 65 years, at the time of signing the informed
             consent.

          -  Participants who are overtly healthy as determined by medical evaluation including
             medical history, physical examination, laboratory tests, and cardiac monitoring. A
             participant with a clinical abnormality or laboratory parameters not specifically
             listed in the exclusion criteria that is outside the reference range for the
             population being studied may be included only if the investigator, in consultation
             with the Medical Monitor (if required), agree and document that the finding is
             unlikely to introduce additional risk factors and will not interfere with the study
             procedures or results.

          -  Japanese participants are eligible based on meeting all of the following criteria:
             healthy male and female participants born in Japan; are descendants of four ethnic
             Japanese grandparents and two ethnic Japanese parents; holding a Japanese passport or
             identity papers; being able to speak Japanese; have lived outside Japan for less than
             10 years at the time of screening.

          -  Chinese Participants are eligible based on meeting all of the following: healthy male
             and female participants born in mainland China; are descendants of four Chinese
             grandparents and two Chinese parents; holding a Chinese passport or identity papers;
             being able to speak Chinese; have lived outside China for less than 10 years at the
             time of screening; Body weight 35-150 kilogram (kg) and body mass index (BMI) within
             the range 18-32 kilogram per square meter (kg/m2) (inclusive).

          -  Female participant: A female participant is eligible to participate if she is not
             pregnant or breastfeeding, and at least one of the following conditions applies; is
             not a woman of childbearing potential (WOCBP) or is a WOCBP and using an acceptable
             contraceptive method during the intervention period (at a minimum until after the last
             dose of study intervention); the investigator should evaluate the effectiveness of the
             contraceptive method in relationship to the first dose of study intervention; a WOCBP
             must have a negative highly sensitive pregnancy test ([urine] as required by local
             regulations) within 24 hours before the first dose of study intervention; if a urine
             test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy
             test is required,. In such cases, the participant must be excluded from participation
             if the serum pregnancy result is positive; additional requirements for pregnancy
             testing during and after study intervention are located; The investigator is
             responsible for review of medical history, menstrual history, and recent sexual
             activity to decrease the risk for inclusion of a woman with an early undetected
             pregnancy.

          -  Contraceptive use by men or women should be consistent with local regulations
             regarding the methods of contraception for those participating in clinical studies.

          -  Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions listed in the informed consent form (ICF) and in this
             protocol.

        Exclusion Criteria:

          -  Alanine transaminase (ALT) >2 times of (x) upper limit of normal (ULN).

          -  Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is
             fractionated and direct bilirubin <35 percent [%]).

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  Ongoing or recurrent infections.

          -  QT interval corrected for heart rate by Fridericia's formula (QTcF) >450 millisecond
             (msec) or any of the following abnormal and clinically significant electrocardiogram
             (ECG) findings; sinus bradycardia <45 beats per minute (bpm); sinus tachycardia >=110
             bpm; multifocal atrial tachycardia (wandering atrial pacemaker with rate >100 bpm);
             evidence of Mobitz II second degree or third degree atrioventricular (AV) block;
             pathological Q waves (defined as wide [>0.04 seconds] and deep [>0.4 millivolt (mV) (4
             millimeter (mm) with 10mm/mV setting)] or >25% of the height of the corresponding R
             wave, providing the R wave was >0.5 mV [5 mm with 10mm/mV setting], appearing in at
             least two contiguous leads; Evidence of ventricular ectopic couplets, bigeminy,
             trigeminy or multifocal premature ventricular complexes; For participants without
             complete right bundle branch block: QT interval corrected for heart rate by
             Fridericia's formula (QTc[F]) >=450 msec or an ECG that is unsuitable for QT
             measurements (e.g., poor defined termination of the T wave); for participants with
             complete right bundle branch block: QTc(F) >=480 msec or an ECG that is unsuitable for
             QT measurements (e.g., poor defined termination of the T wave); ST-T wave
             abnormalities (excluding non-specific ST-T wave abnormalities); Clinically significant
             conduction abnormalities (e.g., Wolff-Parkinson-White syndrome or bifascicular block
             defined as complete left bundle branch block or complete right bundle branch block
             with concomitant left fascicular block); Clinically significant arrhythmias (e.g.,
             atrial fibrillation with rapid ventricular response, ventricular tachycardia).

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including saint [St] John's Wort) within 7 days (or 14 days if the drug
             is a potential enzyme inducer) or 5 half-lives (whichever is longer) before the first
             dose of study medication and until study completion, unless in the opinion of the
             investigator and GlaxoSmithKline (GSK) Medical Monitor the medication will not
             interfere with the study procedures or compromise participant safety.

          -  The participant has been in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Presence of Hepatitis B surface antigen (HBsAg) at screening or within 3 months prior
             to first dose of study intervention.

          -  Positive Hepatitis C antibody test result at screening or within 3 months prior to
             first dose of study intervention.

          -  Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3
             months prior to first dose of study intervention.

          -  A positive test for human immunodeficiency virus (HIV) antibody.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 milliliter (mL) within 3 months.

          -  A positive pre-study drug/alcohol screen.

          -  Any history of substance abuse or a positive test for drugs of abuse at screening or
             admission.

          -  Known, pre-existing parasitic infestations within 6 months prior to Screening.

          -  Vaccinated with live or attenuated vaccines within 4 weeks prior to receiving
             investigational product (IP) and up to 6 months after dose administration of
             GSK3772847.

          -  A positive highly sensitive pregnancy test (urine or serum as required by local
             regulations) at screening.

          -  Positive urinary cotinine test indicative of smoking history at screening or each
             in-house admission to the clinical research unit or regular use of tobacco- or
             nicotine-containing products (e.g. nicotine patches or vaporizing devices) within 6
             months prior to screening.

          -  Participants with allergy or intolerance to a monoclonal antibody or biologic or to
             any components of the formulation used in this study.

          -  A vulnerable participant. defined as individuals whose willingness to volunteer in a
             clinical trial may be unduly influenced by the expectation, whether justified or not,
             of benefits associated with participation, or of a retaliatory response from senior
             members of a hierarchy in case of refusal to participate.

          -  Participants who work for the Sponsor, contract research organization (CRO), or one of
             the study centers.